RNA interference drug developer SanegeneBio leads our round-up of this week's biotech financings, with a $110 million Series B backed by recent partner Eli Lilly. SanegeneBio, a biotech company with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback